• 1
    Khot UN, Khot MB, Bajzer CT. et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898904.
  • 2
    Ridker PM, Rifai N, Rose L. et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:15571565.
  • 3
    Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat Clin Pract Cardiovasc Med. 2005;2:2936.
  • 4
    Ridker PM, Hennekens CH, Buring JE. et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836843.
  • 5
    Biasucci LM, Liuzzo G, Grillo RL. et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999;99:855860.
  • 6
    Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417424.
  • 7
    Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:20072011.
  • 8
    Ridker PM, Rifai N, Pfeffer MA. et al., for the Cholesterol and Recurrent Events (CARE) Investigators. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 1998;98:839844.
  • 9
    Ridker PM. Inflammatory biomarkers, statins, and the risk of stroke: cracking a clinical conundrum. Circulation. 2002;105:25832585.
  • 10
    Albert CM, Ma J, Rifai N. et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105:25952599.
  • 11
    Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA. 2001;285:24812485.
  • 12
    Blake GJ, Ridker PM. C-reactive protein and prognosis after percutaneous coronary intervention. Eur Heart J. 2002;23:923925.
  • 13
    Blake GJ, Rifai N, Buring JE. et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:29932999.
  • 14
    Ridker PM, Rifai N, Cook NR. et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294:326333.
  • 15
    Cushman M, Arnond AM, Psaty BM. et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study. Circulation. 2005;112:2531.
  • 16
    The Exper. Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:31433421.
  • 17
    Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356359.
  • 18
    Lau DC, Dhillon B, Yan H. et al. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol. 2005;288:H2031H2041.
  • 19
    Grundy SM. Inflammation, metabolic syndrome, and diet responsiveness. Circulation. 2003;108:126128.
  • 20
    Ridker PM, Buring JE, Cook NR. et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391397.
  • 21
    Yudkin JS, Stehouwer CDA, Emeis JJ. et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Tromb Vasc Biol. 1999;19:972978.
  • 22
    Ridker PM, Wilson PWF, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation. 2004;109:28182825.
  • 23
    Pradhan AD, Manson JE, Rifai N. et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327334.
  • 24
    Visser M, Bouter LM, McQuillan GM. et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:21312135.
  • 25
    Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289:17991804.
  • 26
    Verma S, Wang CH, Weisel RD. et al. Hyperglycemia potentiates the proatherogenic effects of C-reactive protein: reversal with rosiglitazone. J Mol Cell Cardiol. 2003;35:417419.
  • 27
    Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000;342:17921801.
  • 28
    Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Tromb Vasc Biol. 1998;18:16.
  • 29
    Lau D, Yan H, Abdel-Hafez M, et al. Adipokines and the paracrine control of their production in obesity and diabetes. Int J Obes Relat Metab Disord. 2002;26(suppl 2):S111.
  • 30
    Ouchi N, Kihara S, Funahashi T. et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation. 2003;107:671674.
  • 31
    Yeh ET, Willerson JT. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation. 2003;107:370372.
  • 32
    Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation. 2004;109:19551959.
  • 33
    Pearson TA, Mensah GA, Alexander RW. et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499511.
  • 34
    Biasucci LM. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice. Clinical use of inflammatory markers in patients with cardiovascular disease: a background paper. Circulation. 2004;110:e560e567.
  • 35
    Ridker PM, Rifai N, Clearfield M. et al., for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:19591965.
  • 36
    Ridker PM, Rifai N, Pfeffer MA. et al., for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230235.
  • 37
    Albert MA, Danielson E, Rifai N. et al., for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:6470.
  • 38
    Kinlay S, Schwartz GG, Olsson AG. et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108:15601566.
  • 39
    Nissen SE, Tuzcu EM, Schoenhagen P. et al., for the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:2938.
  • 40
    Ridker PM, Cannon CP, Morrow D, et al., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy—Trombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:2028.
  • 41
    Ridker PM, on behalf of the JUPITER study group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensititivty C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108:22922297.